Iran-Made Factor 13 Deficiency Kit Diagnoses Hereditary Disorders
“We have developed laboratory diagnostic kits that will help prevent the spread and increase of genetic diseases. Our focus is on bleeding disorders, specially factor 13 deficiency,” said Akbar Dorgalaleh, the managing director of the knowledge-based company.
“Factor 13 is one of the proteins involved in blood clotting. Factor 13 deficiency is a rare hereditary disorder that causes abnormal bleeding due to the lack of functional factor 13. Our focus has been on diagnosing bleeding disorders such as hemophilia,” he added.
“Many babies in our country die after birth due to cerebral hemorrhage or umbilical cord bleeding. Our diagnostic kit is designed and manufactured in such a way that it can be used even in rural areas. This product has reduced mortality from factor 13 disease,” Dorgalaleh said.
In a relevant development in November, researchers at a knowledge-based company in Iran had introduced a kit to the market which can detect the occurrence of heart attacks with high accuracy through a blood sample.
Hamed Bagheri, the managing director of an Iranian knowledge-based company, said that the heart attack diagnosis kit, as one of the products made in his company, can save the country $6 million each year to import it.
“Now, we are capable to locally produce the kit and selling to the costumers gaining more than 10% of the market share in the last 10 months,” he went on to say.
He said that one of the competitive advantages of their product compared to foreign equivalents is the lower cost due to acquiring its technical knowledge by the company's researchers and stated, “This product's price is 20% lower than Chinese counterpart and this has helped us to take market share from importers.”
“After a heart attack, the cardiac troponin marker (cTnI) is released into the blood by the damaged heart muscle. The level of this marker remains high between 6 and 10 days after the injury and is used as a marker to diagnose a heart attack,” he said.
“Troponin is present in the cardiac muscle, and together with troponin T and troponin C, it forms a three-subunit complex, and this complex, together with tropomyosin, plays a vital role in transmitting contraction signals in skeletal muscles. Following heart tissue injury due to myocardial infarction, troponin is released into the blood 4 to 6 hours after the start of pain, and its concentration remains high for 6 to 10 days.”
4155/v
